While elevated TNF-a detected at the early onset of disease is a strong indicator for the early recognition of HHV-6 reactivation, this finding also reflects important therapeutic information that could be used as an early diagnostic marker of DIHS/DRESS.
Branka Horvat, MD, PhD, Director of Research at the International Centre for Infectiology Research in Lyon, France (INSERM), and her doctoral student Josephine Reynaud have recently published an important paper on a new transgenic mouse model
Additional evidence that shortened telomeres can cause the release and possible activation of integrated HHV-6.
Dr. Yoshizo Asano and colleagues in Japan report that in measles immunosuppression, cells sensitized to HHV-6B immediate early and early antigen proteins may suppress replication cycles and virus formation, resulting in an “incomplete” subclinical state of reactivation.
We are pleased to announce that with the help of a few HHV-6 specialists, especially Prof. Louis Flamand from Canada, we have generated the monoclonal antibody DR-7.
An international group of experts summarize the significant differences between the two viruses.
A group led by Steven Zeichner has published evidence that suggests the replication of all human herpesviruses can be activated by apoptosis.
Could treatment of HHV-6A co-infections slow AIDS progression?
Japanese group identifies several cytokine and chemokine responses associated with HHV-6B encephalopathy.
HHV-6A and HHV-6B each express distinct chemokines that are uniquely capable of activating key inflammatory cytokines.
CD134, a member of the TNF receptor superfamily, has now been shown as a specific entry receptor for HHV-6B.
A laboratory at the University of Wurzburg has published evidence that Chlamydia trachomatis may induce the activation of ciHHV-6.
A group from France has reported new findings which may help explain the mystery behind the increased rates of HHV-6 reactivation and encephalitis observed among umbilical cord blood transplant (CBT) patients.
A new study has reported that the use of Bortezomib, known commercially as Velcade, may increase the risk of HHV-6 reactivation in myeloma patients undergoing stem cell transplantation.
Findings indicate that HHV-6 infection leads to decreased glutathione production, increased oxidative stress, and induces chlamydial persistence during co-infection